Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE), a medical technology company focused on fluid management solutions, announced its participation in a Virtual Investor segment to discuss a significant $3 million NIH grant awarded to its development partner, Koronis Biomedical Technologies Corporation (KBT).
The grant will support the development of Vivian™, a pediatric continuous renal replacement therapy (CRRT) device designed for patients under 20 kilograms. Additionally, the funding will help advance core software and firmware development that will benefit Nuwellis' broader product portfolio.
Positive
- None.
Negative
- Development partnership structure may limit direct control over project
- Multi-year timeline suggests extended period before potential commercialization
News Market Reaction – NUWE
On the day this news was published, NUWE declined 3.87%, reflecting a moderate negative market reaction. Argus tracked a peak move of +15.5% during that session. Argus tracked a trough of -15.0% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $144K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 12.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Watch the “What This Means” segment here
MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it participated in a Virtual Investor “What This Means” segment.
For the segment, Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately
The Virtual Investor “What this Means” segment featuring Nuwellis is now available here.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
For further information, please contact:
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
nuwe@jtcir.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ
What is the value of the NIH grant awarded to Nuwellis' development partner?
What is Nuwellis' Vivian™ device designed for?
How will the NIH grant benefit Nuwellis (NUWE)?
Who is Nuwellis' development partner for the NIH-funded project?
What type of company is Nuwellis (NUWE)?
